Equillium
27 hedge funds and large institutions have $7.44M invested in Equillium in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 5 closing their positions.
240% more call options, than puts
Call options by funds: $17K | Put options by funds: $5K
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
2.46% less ownership
Funds ownership: 31.29% → 28.83% (-2.5%)
4% less funds holding
Funds holding: 28 → 27 (-1)
5% less capital invested
Capital invested by funds: $7.86M → $7.44M (-$422K)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$234K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$206K |
| 3 |
Prudential Financial
Newark,
New Jersey
|
+$38.2K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$19.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$449K |
| 2 |
JP Morgan Chase
New York
|
-$283K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$252K |
| 4 |
Millennium Management
New York
|
-$56K |
| 5 |
DA
DCF Advisers
Greenwich,
Connecticut
|
-$30K |
EQ Hedge Fund Activity: Q2 2023 in Review
27 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Equillium (EQ) for Q2 2023, worth a combined $7.44M — down 5.4% from $7.86M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of EQ and 4 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $234K. The largest seller was Samsara BioCapital, exiting entirely with an estimated $449K sold.
- 27 institutional investors held Equillium (EQ) as of Q2 2023, down from 28 in Q1 2023.
- Funds reported $7.44M of Equillium stock for Q2 2023, down 5.4% quarter-over-quarter.
- 4 funds opened new Equillium positions in Q2 2023 and 5 closed out, a net change of -1 holder.
- The largest Equillium buyer in Q2 2023 was Renaissance Technologies, an estimated $234K added.
- The largest Equillium seller in Q2 2023 was Samsara BioCapital, an estimated $449K sold.
Based on aggregated 13F filings for Q2 2023.